Press ReleaseView printer-friendly version << Back
Audentes to Release Second Quarter 2018 Financial Results and Provide Update on ASPIRO, the Phase 1/2 study of AT132 in Patients with X-Linked Myotubular Myopathy
The conference call and webcast will be held on
A replay of the live webcast will be available on the Audentes website for approximately 30 days.
About AT132 for X-Linked Myotubular Myopathy
AT132 is the Audentes product candidate being developed to treat XLMTM, a rare monogenic disease characterized by extreme muscle weakness, respiratory failure and early death, with an estimated 50% mortality rate by 18 months of age. XLMTM is caused by mutations in the MTM1 gene, which encodes the protein myotubularin. Myotubularin plays an important role in the development, maintenance and function of skeletal muscle cells. AT132 is comprised of an AAV8 vector containing a functional copy of the MTM1 gene. In May 2018, Audentes reported positive interim data from the first dose cohort of ASPIRO, a multicenter, ascending dose Phase 1 / 2 clinical study to evaluate the safety and preliminary efficacy of AT132 in approximately 12 XLMTM patients less than five years of age. The preclinical development of AT132 was conducted in collaboration with Genethon (www.genethon.fr).
AT132 has been granted PRIME and Orphan Drug designations by the EMA, and Rare Pediatric Disease, Fast Track and Orphan Drug designations by the FDA.
About Audentes Therapeutics, Inc.
For more information regarding Audentes, please visit www.audentestx.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/audentes-to-release-second-quarter-2018-financial-results-and-provide-update-on-aspiro-the-phase-12-study-of-at132-in-patients-with-x-linked-myotubular-myopathy-300688571.html